Granuloma Fluid and Stem Cells for Exercise-Induced Pulmonary Hemorrhage
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for exercise-induced pulmonary hemorrhage (EIPH) in animals, such as horses, are often ineffective and come with significant side effects, with furosemide being banned in some countries due to its diuretic effects and potential health risks.
Innovation Solution
Administration of a pharmaceutical composition comprising granuloma fluid or cells, specifically mesenchymal stem cells, which can be administered via various routes including nasal and pulmonary, to reduce the severity of EIPH.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If furosemide is administered to treat EIPH, then diuretic effects are achieved, but dehydration and electrolyte imbalance occur
Solution Approach 1:
The patent introduces a new therapeutic agent (granuloma fluid or stem cells) as an intermediary to treat EIPH through a different mechanism that does not involve diuresis. This mediator addresses the bleeding issue without causing dehydration or electrolyte imbalance, thus resolving the contradiction between treatment efficacy and harmful side effects
Solution Approach 2:
The invention changes the therapeutic parameter from diuretic action to regenerative/anti-inflammatory action. By administering granuloma fluid or stem cells, the treatment mechanism shifts from reducing fluid volume to promoting tissue repair and reducing inflammation, thereby eliminating the harmful effects while maintaining treatment efficacy
2Productivity
If furosemide is used to improve racing times, then performance enhancement is achieved, but the substance is banned and health risks increase
Solution Approach 1:
The patent employs stem cells or granuloma fluid as a temporary, non-persistent treatment that does not accumulate in the system like furosemide. This approach provides performance benefit without creating long-term health risks or violating bans on persistent substances
Solution Approach 2:
A new therapeutic intermediary (stem cells or granuloma fluid) replaces furosemide as the performance-enhancing agent. This mediator works through tissue repair and inflammation reduction rather than diuresis, achieving performance improvement without the banned substance status and associated health risks
3Object-affected harmful factors
If anti-inflammatory agents are administered to treat EIPH, then inflammation is reduced, but treatment effectiveness is limited
Solution Approach 1:
The patent employs stem cells that possess intrinsic self-service capabilities to treat EIPH. These cells can self-differentiate, self-organize, and actively promote tissue repair and regeneration without requiring continuous external anti-inflammatory intervention, thereby overcoming the limitations of conventional anti-inflammatory agents
Solution Approach 2:
The invention uses granuloma fluid containing multiple bioactive components (growth factors, cytokines, extracellular matrix) as a composite therapeutic agent. This composite material provides multifaceted effects including anti-inflammatory, regenerative, and protective actions, surpassing the single-mechanism approach of conventional anti-inflammatory drugs
Data Source
AI summary
Provided herein are methods of treating EIPH in a subject in need thereof. The methods comprise administering an effective amount of a pharmaceutical composition to the subject. In some embodiments, the pharmaceutical composition comprises a granuloma fluid, or a composition derived from a granuloma fluid. In some embodiments, the pharmaceutical composition comprises a cell. These pharmaceutical compositions may be administered by any suitable route of administration, and may be administered with one or more further therapeutic agents. Also provided are kits comprising pharmaceutical compositions for use with the methods provided herein.